So far the data, with a Car-T Legend licensed to Novartis, lag antibody approaches.
ApexOnco Front Page
Recent articles
Inlexzo gets the nod in BCG-unresponsive non-muscle invasive bladder cancer, but the group has bigger plans.
Zanzalintinib prevails in all comers, but full data will show if the win was driven by a subgroup.
Sunmo succeeds in a setting very similar to Starglo's.
The registrational part 2 of bezuclastinib's Summit trial reads out in July.
When your investment case breaks down, why not just do the decent thing?
A new KRAS degrader and PD-1 x Lag3 bispecific have just started phase 1.
Suzhou Zelgen’s DLL3 x DLL3 project looks better than regular T-cell engagers, with caveats.
